To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants

NCT05189548 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety、Immunogenicity

Interventions

BIOLOGICAL: A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine

Sponsor

Changchun BCHT Biotechnology Co.